Table 1.

Distribution of selected variables according to Taxane users (n = 35) vs. no taxane (Control cohort n = 41): Univariate analysis.

	Patients		p-value*	OR (95% CI)**
	Control cohort n (%)	Taxane users n (%)
Age			0.06
<60	17 (41.5)	22 (62.9)		1
≥60	24 (58.5)	13 (37.1)		0.42 (0.16–1.06)
Gender			0.04
Male	20 (48.8)	9 (25.7)		1
Female	21 (51.2)	26 (74.3)		2.75 (1.04–7.29)
Type of cancer			nd
Breast	14	7
Genitouranary	8	11
Gastric	1	2
Other	18	15
Adverse events			0.001
No	29 (70.7)	12 (34.3)		1
Yes	12 (29.3)	23 (65.7)		4.7 (1.82–12.6)
Neutro & Neuro			0.003
No	29 (70.7)	12 (34.3)		1
G1 & G2	11 (26.8)	18 (51.4)		4.09 (1.49–11.18)
G3 & G4	1 (2.4)	5 (14.3)		12.5 (1.32–118.47)
Neutropenia			0.02
No	37 (90.2)	24 (68.6)		1
Yes	4 (9.8)	11 (31.4)		4.35 (1.24–15.25)
Neuropathy			0.3
No	37 (90.2)	29 (82.9)		1
Yes	4 (9.8)	6 (17.1)		1.96 (0.51–7.62)

^*Chi-Square test;

^**Crude odds ratio logistic regression were adjusted for age and gender. In bold are significative results.